<?xml version="1.0" encoding="UTF-8"?>
<p id="Par22">We found no significant evidence to suggest that the increasing abundance of 
 <italic>Porphyromonas</italic>, 
 <italic>Prevotella</italic>, or 
 <italic>Corynebacterium_1</italic> (cluster 1) correlated with levodopa therapy. We did find significant evidence (two-sided 
 <italic>P</italic>-value &lt; 0.05) in dataset 2 to suggest that increasing doses of levodopa were correlated with decreasing levels of SCFA-producing organisms (
 <italic>Faecalibacterium</italic>
 <italic>P</italic> = 0.01, 
 <italic>Agathobacter</italic>
 <italic>P</italic> = 0.02, 
 <italic>Blautia</italic>
 <italic>P</italic> = 5E − 4, 
 <italic>Roseburia</italic>
 <italic>P</italic> = 0.02, 
 <italic>Fusicatenibacter</italic>
 <italic>P</italic> = 0.01, 
 <italic>Lachnospira</italic>
 <italic>P</italic> = 5E − 3
 <italic>, Lachnospiraceae_ND3007_group</italic>
 <italic>P</italic> = 5E − 3
 <italic>, Lachnospiraceae_UCG-004</italic>
 <italic>P</italic> = 0.03). A similar pattern was present in dataset 1, albeit most did not reach statistical significance possibly due to the smaller sample size of dataset 1. We also detected significant correlation between increasing levodopa dose and increasing levels of 
 <italic>Bifidobacterium</italic> (dataset 1 
 <italic>P</italic> = 5E − 3, dataset 2 
 <italic>P</italic> = 2E − 6) and 
 <italic>Lactobacillus</italic> (dataset 2 
 <italic>P</italic> = 4E − 3). These data suggest that the increase in abundance of cluster 1 (opportunistic pathogens) is independent of levodopa, but that the reduction in cluster 2 (SCFA) and increase in cluster 3 (probiotics), if not solely a consequence of medication, worsen with increasing doses of levodopa.
</p>
